Investors

MSC-NTF cells

Autologous MSC-NTF cells are a therapeutic candidate targeting disease pathways important in neurodegenerative disorders.

02

Differentiation

A patient’s own mesenchymal stromal cells (MSCs) are harvested and differentiated to secrete high levels of neurotrophic factors (NTFs) using a proprietary technology. The differentiated cells are then harvested and prepared for injection. They are not genetically modified, and can deliver multiple NTFs and immunomodulatory cytokines directly to the site of damage.

Before differentiation - MSCs
After differentiation - MSC-NTF cells

Source: BrainStorm, data on file. Detection of GDNF expression in MSC and MSC-NTF cells by immunofluorescence.

NTF levels before and after differentiation

Four-panel chart comparing BDNF, GDNF, VEGF and HGF levels in MSCs before differentiation with MSC-NTF cells after differentiation

Source: BrainStorm, data on file. BDNF: Brain-derived neurotrophic factor; GDNF: Glial-derived neurotrophic factor; HGF: Hepatocyte growth factor; VEGF: Vascular endothelial growth factor.

Mechanism of action

Secreted factors and pathways

Autologous MSC-NTF cells secrete a unique profile of bioactive molecules, including NTFs, microRNA and cytokines.

Following intrathecal administration, the autologous MSC-NTF cells may activate neuroprotective and immunomodulatory pathways.

Read next

BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.